Results 31 to 40 of about 10,088 (191)
Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study [PDF]
Aim Gut microbial dysbiosis is implicated in the pathogenesis of non-alcoholic steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin ...
Atkinson, Stephen +65 more
core +1 more source
Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of rifaximin and lactulose could yield additional benefits for patients with HE are limited and inconclusive.
Jian Fu, Yi Gao, Li Shi
doaj +2 more sources
Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis
Background Rifaximin is a poorly absorbed broad-spectrum antibiotic used for hepatic encephalopathy. Although increased Lactobacillaceae and decreased Bacteroidetes abundance are characteristic of hepatic encephalopathy, rifaximin does not dramatically ...
Kazuhiko Ikeuchi +7 more
doaj +1 more source
Review of rifaximin: a summary of the current evidence and its benefits beyond its licensed use
Antibiotic resistance in patients with cirrhosis continues to draw significant attention. With a propensity to frequent hospitalisations, cirrhotics are subject to frequent antibiotic prescription.
Nathwani, Rooshi +11 more
core +1 more source
RIFAXIMIN INDUCED HYPONATREMIA: A CASE REPORT [PDF]
Rifaximin is one of the common drugs used in clinical practice in the management of traveler\u27s diarrhea, irritable bowel syndrome (IBS), and hepaticencephalopathy. Hyponatremia is one of the rare side effects of this drug.
Upadhyay, Shalini +3 more
core +3 more sources
Introduction Periprosthetic joint infections (PJI) are a major complication in joint-arthroplasty. Rifampicin is often used as an additional agent to treat PJI, because it penetrates bacterial biofilms.
Uta S. Koepf +6 more
doaj +1 more source
Background: Norfloxacin is the most commonly used agent for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis.
Mohammed M. Shamseya, Marwa A. Madkour
doaj +1 more source
Background. Inflammatory bowel disease results from the dysregulation of immune response to environmental and microbial agents in genetically susceptible individuals.
Artur Dembiński +9 more
doaj +1 more source
BackgroundRifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP).AimTo detect the impact of rifaximin on the occurrence and ...
Philipp Lutz +8 more
doaj +1 more source
Background. Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. However, there is no uniform view on the efficacy and safety of rifaximin. Methods.
Dong Wu +5 more
doaj +1 more source

